We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · February 08, 2021

Neoantigen Therapy Plus Anti–PD-1 in Patients With Advanced Melanoma, NSCLC, or Bladder Cancer



Additional Info

Disclosure statements are available on the authors' profiles:

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Bladder Cancer
Cell 2020 Oct 15;183(2)347-362.e24, PA Ott, S Hu-Lieskovan, B Chmielowski, R Govindan, A Naing, N Bhardwaj, K Margolin, MM Awad, MD Hellmann, JJ Lin, T Friedlander, ME Bushway, KN Balogh, TE Sciuto, V Kohler, SJ Turnbull, R Besada, RR Curran, B Trapp, J Scherer, A Poran, D Harjanto, D Barthelme, YS Ting, JZ Dong, Y Ware, Y Huang, Z Huang, A Wanamaker, LD Cleary, MA Moles, K Manson, J Greshock, ZS Khondker, E Fritsch, MS Rooney, M DeMario, RB Gaynor, L Srinivasan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading